Expleo Solutions Future Growth
Future criteria checks 0/6
Expleo Solutions's EPS is expected to grow by 26.8% per annum.
Key information
n/a
Earnings growth rate
26.8%
EPS growth rate
IT earnings growth | 11.0% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 17 Jul 2024 |
Recent future growth updates
Recent updates
Further Upside For Expleo Solutions Limited (NSE:EXPLEOSOL) Shares Could Introduce Price Risks After 25% Bounce
Dec 18Expleo Solutions' (NSE:EXPLEOSOL) Conservative Accounting Might Explain Soft Earnings
Nov 22Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 24When Should You Buy Expleo Solutions Limited (NSE:EXPLEOSOL)?
Jun 21Investors Could Be Concerned With Expleo Solutions' (NSE:EXPLEOSOL) Returns On Capital
Mar 15The Returns On Capital At Expleo Solutions (NSE:EXPLEOSOL) Don't Inspire Confidence
Sep 15Increases to Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Might Cool off for now
Aug 19Calculating The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Jul 14Many Would Be Envious Of Expleo Solutions' (NSE:EXPLEOSOL) Excellent Returns On Capital
May 05A Look At The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Mar 15Expleo Solutions Limited's (NSE:EXPLEOSOL) Stock Been Rising: Are Strong Financials Guiding The Market?
Feb 15Expleo Solutions (NSE:EXPLEOSOL) Knows How to Allocate Capital
Jan 24Introducing Expleo Solutions (NSE:EXPLEOSOL), A Stock That Climbed 76% In The Last Year
Jan 04A Look At The Intrinsic Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Dec 14Is There More To The Story Than Expleo Solutions's (NSE:EXPLEOSOL) Earnings Growth?
Nov 26Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2025 | 11,322 | N/A | N/A | N/A | 1 |
9/30/2024 | 10,171 | 1,091 | 1,522 | 1,697 | N/A |
6/30/2024 | 9,919 | 942 | N/A | N/A | N/A |
3/31/2024 | 9,649 | 904 | 517 | 692 | N/A |
12/31/2023 | 9,405 | 1,038 | N/A | N/A | N/A |
9/30/2023 | 9,305 | 1,251 | 130 | 380 | N/A |
6/30/2023 | 9,152 | 1,311 | N/A | N/A | N/A |
3/31/2023 | 9,033 | 1,339 | -211 | 231 | N/A |
12/31/2022 | 5,072 | 823 | N/A | N/A | N/A |
9/30/2022 | 4,779 | 648 | 73 | 420 | N/A |
6/30/2022 | 4,439 | 583 | N/A | N/A | N/A |
3/31/2022 | 7,425 | 677 | -12 | 242 | N/A |
12/31/2021 | 3,703 | 463 | N/A | N/A | N/A |
9/30/2021 | 3,366 | 475 | 529 | 588 | N/A |
6/30/2021 | 3,131 | 490 | N/A | N/A | N/A |
3/31/2021 | 3,009 | 504 | 620 | 664 | N/A |
12/31/2020 | 2,971 | 534 | N/A | N/A | N/A |
9/30/2020 | 2,931 | 512 | 332 | 373 | N/A |
6/30/2020 | 2,852 | 475 | N/A | N/A | N/A |
3/31/2020 | 2,702 | 399 | 144 | 167 | N/A |
12/31/2019 | 2,627 | 353 | N/A | N/A | N/A |
9/30/2019 | 2,614 | 298 | 274 | 295 | N/A |
6/30/2019 | 2,741 | 345 | N/A | N/A | N/A |
3/31/2019 | 2,865 | 362 | 382 | 406 | N/A |
12/31/2018 | 2,973 | 372 | N/A | N/A | N/A |
9/30/2018 | 2,949 | 377 | N/A | N/A | N/A |
6/30/2018 | 2,898 | 313 | N/A | N/A | N/A |
3/31/2018 | 2,764 | 320 | N/A | 250 | N/A |
12/31/2017 | 2,583 | 256 | N/A | N/A | N/A |
9/30/2017 | 2,488 | 243 | N/A | N/A | N/A |
6/30/2017 | 2,475 | 230 | N/A | N/A | N/A |
3/31/2017 | 2,599 | 238 | N/A | 423 | N/A |
12/31/2016 | 2,747 | 293 | N/A | N/A | N/A |
9/30/2016 | 2,809 | 329 | N/A | N/A | N/A |
6/30/2016 | 2,790 | 372 | N/A | N/A | N/A |
3/31/2016 | 2,642 | 369 | N/A | 577 | N/A |
12/31/2015 | 2,445 | 279 | N/A | N/A | N/A |
9/30/2015 | 2,312 | 271 | N/A | N/A | N/A |
6/30/2015 | 2,212 | 240 | N/A | N/A | N/A |
3/31/2015 | 2,142 | 216 | N/A | 334 | N/A |
12/31/2014 | 2,116 | 222 | N/A | N/A | N/A |
9/30/2014 | 2,087 | 226 | N/A | N/A | N/A |
6/30/2014 | 2,027 | 261 | N/A | N/A | N/A |
3/31/2014 | 1,944 | 300 | N/A | 237 | N/A |
12/31/2013 | 1,819 | 300 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EXPLEOSOL's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if EXPLEOSOL's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if EXPLEOSOL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if EXPLEOSOL's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if EXPLEOSOL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EXPLEOSOL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 03:42 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Expleo Solutions Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Anil Burra | FirstCall Research |
Naveed MD. | FirstCall Research |
Abhay Moghe | IL&FS Broking Services Private Limited |